Immunomedics Coverage Initiated by Analysts at Chardan Capital (IMMU)
Investment analysts at Chardan Capital initiated coverage on shares of Immunomedics (NASDAQ:IMMU) in a note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $9.00 price target on the stock. Chardan Capital’s price target would suggest a potential upside of 85.57% from the company’s current price.
Immunomedics (NASDAQ:IMMU) traded up 1.86% during mid-day trading on Wednesday, hitting $4.94. 412,320 shares of the company’s stock traded hands. Immunomedics has a one year low of $2.11 and a one year high of $7.35. The stock’s 50-day moving average is $4.27 and its 200-day moving average is $5.10. The company’s market cap is $410.7 million.
Develops antibody-based medical products used to detect, diagnose and treat cancer. The Company is particularly focused on developing products in the following areas: in-vitro diagnostic tests for the detection of cancer and certain autoimmune diseases; in-vivo imaging products for the early detection and diagnosis of cancer using a method called radioimmunodetection; in-vivo therapeutic products used in the targeted delivery of therapeutic doses of radioisotopes colorectal and gastrointestinal cancer tissues.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.